最高の Medicom Oncology ポッドキャスト (2024)

1
Third-generation FLT3 inhibitors in clinical development 2:42

5+ y ago2:42

2:42

Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.MediCom Oncology による

1
CAR T case study in acute myeloid leukemia 5:49

5+ y ago5:49

5:49

Dr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.MediCom Oncology による

1
Key considerations when prescribing midostaurin with a strong CYP3A4 inhibi 2:23

5+ y ago2:23

2:23

Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.MediCom Oncology による

1
How to proceed with a patient who presents with idiopathic cytopenia of undetermined significance 3:58

6y ago3:58

3:58

In this audio activity, Dr. Goldberg describes his approach to patients with idiopathic or clonal cytopenias of undetermined significance (ICUS and CCUS).MediCom Oncology による

1
When to consider iron chelation therapy for a transplant-eligible patient 3:56

6y ago3:56

3:56

Listen as Dr. Goldberg explains his approach to iron chelation therapy in patients who are, or may be within the next 5-10 years, eligible for transplant.MediCom Oncology による

1
53-year-old woman presenting with severe fatigue and bruising 3:58

6y ago3:58

3:58

Hematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, describing the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics.MediCom Oncology による

1
New subcategories of pancreatic cancer allow for a biomarker-driven approach to therapy 4:00

6+ y ago4:00

4:00

Dr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy.MediCom Oncology による

1
What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics? 2:40

6+ y ago2:40

2:40

Dr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics.MediCom Oncology による

1
Predictors of response to lenalidomide in a non-del(5q) MDS patient 3:03

6+ y ago3:03

3:03

Listen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient.MediCom Oncology による

1
What are the pros and cons of radiation therapy? 2:29

6+ y ago2:29

2:29

Listen as Dr. Matasar discusses the pros and cons of radiation therapy, and who should be offered this therapy.MediCom Oncology による

1
What defines high-quality survivorship care for patients treated for classical Hodgkin lymphoma? 3:01

6+ y ago3:01

3:01

Listen as Dr. Matasar discusses survivorship care for patients who have been treated for classical Hodgkin lymphoma, including late effects of treatment.MediCom Oncology による

1
Second primary malignancies associated with lenalidomide maintenance 2:53

6+ y ago2:53

2:53

Dr. Jacob Laubach discusses second primary malignancies associated with lenalidomide maintenance in the transplant and post-transplant setting.MediCom Oncology による

1
Impact of consolidation therapy in patients post-transplant 3:09

6+ y ago3:09

3:09

Dr. Laubach discusses the impact of consolidation therapy in patients post-transplant, referencing results of the CTN StaMINA trial.MediCom Oncology による

1
Bortezomib as an alternate strategy for maintenance therapy. 2:32

6+ y ago2:32

2:32

Dr. Jacob Laubach discusses bortezomib as an alternate strategy to lenalidomide for maintenance therapy in patients with multiple myeloma.MediCom Oncology による

1
What may be the future role for brentuximab vedotin in newly diagnosed Hodgkin lymphoma? 2:35

6+ y ago2:35

2:35

Listen as Dr. Matasar discusses the future role of brentuximab vedotin in patients with newly diagnosed classical Hodgkin lymphoma.MediCom Oncology による

1
Has MRD testing become a standard of care in multiple myeloma? 3:22

6+ y ago3:22

3:22

Dr. Ruben Niesvizky discusses MRD testing and how it has become a standard of care in multiple myeloma, as well as future directions in MRD testing that will improve outcomes in these patients.MediCom Oncology による

1
The Precision Promise [SM] Initiative: What is it designed to achieve? 4:32

6+ y ago4:32

4:32

Dr. O'Reilly provides an insightful overview of how the emerging use of precision medicine and the Precision Promise [SM] initiative will impact the new drug approval process in pancreatic cancer.MediCom Oncology による

1
Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study 8:26

6+ y ago8:26

8:26

Dr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.MediCom Oncology による

1
What are the optimal imaging methods to determine extent of bone disease in newly diagnosed MM? 3:18

6+ y ago3:18

3:18

Dr. Ruben Niesvizky discusses newer approaches for imaging in patients who have multiple myeloma with bone disease, including the benefits of combining modalities such MRI and PET scan.MediCom Oncology による

1
The standard of care for patients receiving lenalidomide or thalidomide who are at high risk for VTE 3:36

6+ y ago3:36

3:36

Dr. Ruben Niesvizky discusses clinical approaches to managing the risk of developing VTE in myeloma patients receiving immunomodulating agents such as lenalidomide or thalidomide.MediCom Oncology による

1
How do I dose daratumumab, lenalidomide and dexamethasone in the combination regimen? 1:59

6+ y ago1:59

1:59

In under two minutes, Dr. Carol Ann Huff will discuss how to dose daratumumab in conjunction with lenalidomide and dexamethasone in patients with multiple myeloma.MediCom Oncology による

1
Is there a connection between pancreatic cancer and new-onset diabetes? 8:26

6+ y ago8:26

8:26

Dr. Anil Rustgi discusses a clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes.MediCom Oncology による

1
CPX versus 7 and 3 conventional chemotherapy in older adults with AML 3:16

6+ y ago3:16

3:16

Dr. Stuart Goldberg briefly summarizes updates on CPX-351, a liposomal form of cytarabine and daunorubicin that allows for office infusion vs. standard consolidation requiring hospitalization.MediCom Oncology による

1
How long should I be infusing carfilzomib intravenously? 2:55

6+ y ago2:55

2:55

Listen as Dr. Huff discusses the infusion duration for carfilzomib in patients with multiple myeloma.MediCom Oncology による

1
What is the current status of immunotherapy in pancreatic cancer? 4:37

6+ y ago4:37

4:37

Listen as Dr. O'Reilly discusses the the current status of immunotherapy in pancreatic cancer.MediCom Oncology による

1
Measuring Frailty in Patients Being Treated for Multiple Myeloma 1:49

6+ y ago1:49

1:49

Listen for just under two minutes as Dr. Harvey explains measuring frailty in patients being treated for multiple myeloma.MediCom Oncology による

1
Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant IDH2 4:04

6+ y ago4:04

4:04

Dr. Eytan Stein provides a brief update on patients experiencing differentiation syndrome in a larger enasidenib trial, detailing the creation of a Differentiation Syndrome Review Committee.MediCom Oncology による

1
How do I dose daratumumab, bortezomib and dexamethasone in the combination regimen? 3:17

6+ y ago3:17

3:17

Listen as Dr. Carol Ann Huff discusses how to dose daratumumab, bortezomib and dexamethasone in the combination regimen.MediCom Oncology による

1
Update on the CALGB-100104 (Alliance) randomized trial 3:26

6+ y ago3:26

3:26

Listen as Dr. Philip McCarthy provides an update on the CALGB-100104 (Alliance) randomized trial.MediCom Oncology による

1
How does the safety profile of the new and emerging anti-PD 1 antibodies differ from chemotherapy? 1:55

6+ y ago1:55

1:55

Listen as Dr. Alison Moskowitz discusses the difference between the safety profile of the new and emerging anti-PD-1 antibodies and chemotherapy.MediCom Oncology による

1
ELOQUENT-2 updates represent the longest median FU of an immuno-oncology agent in MM 1:43

7y ago1:43

1:43

Dr. Sagar Lonial provides a brief update on the ELOQUENT-2 phase 3 trial and how it continues to demonstrate a benefit in terms of progression-free survival.MediCom Oncology による

1
Optimal Pre-medication Strategy for Daratumumab 2:09

7y ago2:09

2:09

Listen for just under two minutes as Dr. Harvey discusses optimal pre-medications for daratumumab, including H1 antagonists.MediCom Oncology による

1
Rash Management for Patients Taking IRd (Ixazomib-Lenalidomide-Dexamethasone) 1:28

7y ago1:28

1:28

Listen as Dr. Harvey will discuss rash management for patients taking IRd.MediCom Oncology による

1
What is the appropriate management for severe hypercalcemia? 2:31

7y ago2:31

2:31

Listen as Dr. Niesvizky explains the appropriate management for severe hypercalcemia.MediCom Oncology による

1
What is the most common cause of renal failure in newly diagnosed patients with multiple myeloma? 1:54

7y ago1:54

1:54

Listen as Dr. Niesvizky discusses the most common cause of renal failure in newly diagnosed patients with MM.MediCom Oncology による

1
Standard dosing and delivery of Nal-IRI + 5-FU/LV 2:21

7y ago2:21

2:21

Listen as Dr. Wang-Gillam discusses the standard dosing and delivery of Nal-IRI + 5-FU/LV.MediCom Oncology による

1
How important is the availability of supportive care when considering transplant in older patients? 2:26

7y ago2:26

2:26

Listen as Dr. Ritchie discusses the importance of available supportive care when considering transplant in older patients with MDS.MediCom Oncology による

1
Is the AE profile of BV the same or different from traditional monoclonal antibody therapies? 2:09

7y ago2:09

2:09

Listen as Dr. Moskowitz discusses the AE profile of BV and traditional monoclonal antibody therapies.MediCom Oncology による

1
When do you need to do a bone marrow biopsy in the management or assessment of multiple myeloma? 2:37

7y ago2:37

2:37

Listen as Dr. Richter discusses when you need to do a bone marrow biopsy in the management or assessment of multiple myeloma.MediCom Oncology による

1
What are some of the more common adverse reactions associated with brentuximab vedotin? 2:49

7y ago2:49

2:49

Listen as Dr. Moskowitz discusses the more common adverse reactions associated with brentuximab vedotin and how they are most often managed.MediCom Oncology による

1
What are the different technologies used to assess cytogenetic risk status? 2:17

7y ago2:17

2:17

Listen as Dr. Richter will discuss the different technologies used to assess cytogenetic risk status in your myeloma patient.MediCom Oncology による

1
What is meant by the term high-risk myeloma? 2:30

7y ago2:30

2:30

Listen as Dr. Richter will discuss the meaning of high-risk myeloma.MediCom Oncology による

1
Standard dosing and delivery of FOLFIRINOX 2:24

7y ago2:24

2:24

Listen as Dr. Andrea Wang-Gillam explains standard dosing and delivery of FOLFIRNOX in patients with pancreatic cancer.MediCom Oncology による

1
The new FDA approval of pembrolizumab for cHL 4:36

7y ago4:36

4:36

Listen as Dr. Anas Younes covers the new FDA approval of pembrolizumab for patients with cHL.MediCom Oncology による

1
Standard dosing and delivery of gemcitabine/nab-paclitaxel 2:22

7y ago2:22

2:22

Listen as Dr. Andrea Wang-Gillam explains standard dosing and delivery of gemcitabine/nab-paclitaxel in patients with pancreatic cancer.MediCom Oncology による